This story has been updated to clarify GnuBio's commercialization plans.

One week after GnuBio announced that it had expanded into an 11,000-square-foot space as it prepares to enter commercialization, it is already reaching capacity, CEO John Boyce told In Sequence.

The company, which is developing a $50,000 microfluidic sequencer, has nearly doubled its employees over the last year to around 28 and expects to double in size again by the end of next year, Boyce said.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

This year's Breakthrough Prize winners include a pair that developed a therapy for spinal muscular atrophy.

The New York Times reports on how white supremacists misconstrue genetic research, concerning many geneticists.

Researchers find that people's genetics influence their success at university, but that it is not the only factor.

In Nature this week: approach to identify genetic variants that affect trait variability, application of read clouds to microbiome samples, and more.